Therapy News and Research

RSS

Study identifies genetic risk for fatal blood clots in IBD patients

Blood clots are the biggest cause of death in patients with inflammatory bowel disease (IBD) ─ ulcerative colitis or Crohn's disease. In a retrospective study recently published in the journal Gastroenterology, Cedars-Sinai investigators found that a combination of rare and common genetic variants in some IBD patients significantly increased their risk of developing clot-causing thromboembolic diseases.

11 Nov 2020

IU researcher awarded NCI grant to develop a drug for making radiation therapy more effective

An Indiana University Melvin and Bren Simon Comprehensive Cancer Center researcher has been awarded a five-year, $2.9 million grant from the National Cancer Institute to develop a drug that could make radiation therapy far more effective.

11 Nov 2020

Microbes in the lungs could influence lung cancer progression and prognosis

Bottom Line: Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer.

11 Nov 2020

Effectiveness of vitamin C against COVID-19 depends on its natural transporter levels

High doses of vitamin C under study for treating COVID-19 may benefit some populations, but investigators exploring its potential in aging say key factors in effectiveness include levels of the natural transporter needed to get the vitamin inside cells.

11 Nov 2020

Scientists are developing new treatment option for lung fibrosis

A new treatment option for lung fibrosis is being developed by Purdue University scientists. Lung fibrosis has been a concern for COVID-19 patients.

11 Nov 2020

Synthetic protein nanoparticle may treat aggressive brain cancer

A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

11 Nov 2020

Gene signature may help develop new therapies against advanced prostate cancer

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.

11 Nov 2020

Study: SphK2 enzyme regulates immune cell responses during viral infection

Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections.

11 Nov 2020

Study may help develop recovery and prevention paths for gambling addiction

For the first time, new research conducted by SISSA and by the University of Roma Tre identifies narrative markers of gambling addiction and paves the way to innovative approaches for therapy and prevention.

11 Nov 2020

Dietary induction of hepatocyte regeneration may be a viable strategy to enhance gene repair

Use of thyroid hormone to boost hepatocyte proliferation enhanced the efficiency of CRISPR/Cas9-mediated gene correction in the mouse liver.

11 Nov 2020

A promising vaccine for treating poorly immunogenic tumors

Patients with cancer have multiple treatment options available to them today, but each has its drawbacks. Chemotherapy kills rapidly dividing cancer cells, but it also damages healthy cells in the body and often does not effectively prevent tumor metastasis or disease recurrence.

11 Nov 2020

New double-balloon catheter receives Canadian patent

Medical University of South Carolina radiologist assistant Cephus E. Simmons Sr., Ph.D., realized that catheters on the market were not optimal for providing the needed diagnostic yield during radiology procedures.

10 Nov 2020

Semi-automated approach accelerates artificial organoid growth and selection

The method currently used to produce stem cell-derived tissues has a very limited throughput. By semi-automating tissue differentiation, researchers from MIPT and Harvard have made the process nearly four times faster, without compromising on quality.

10 Nov 2020

Repairing brain damage caused by MS

Neurological symptoms as a result of Multiple Sclerosis (MS), such as loss of cognitive or motor function, lead to a great many problems for over 2.5 million people worldwide.

10 Nov 2020

Biodegradable 3D-printed esophageal stents for treating radiation esophagitis

Radiation esophagitis, characterized by the inflammation of the esophagus, is the most common acute adverse effect of radiation therapy that causes swallowing problems.

10 Nov 2020

Identifying SARS-CoV-2 spike protein mutations resistant to antibodies

Using a set of different monoclonal antibodies, researchers determined different mutations in the SARS-CoV-2 spike protein that leads to resistance. Understanding these resistant mutations is important in developing effective therapeutic strategies.

10 Nov 2020

Researchers investigate natural compound for treating amnestic Mild Cognitive Impairment

Greek researchers and clinicians investigated for the first time the effect of High Phenolic Early Harvest Extra Virgin Olive Oil (HP-EH-EVOO) versus Moderate Phenolic (MP-EVOO) and Mediterranean Diet (MeDi) as a therapeutic pharmaceutical natural compound for older adults with amnestic Mild Cognitive Impairment (aMCI).

10 Nov 2020

Lupus Research Alliance announces the 2020 Lupus Innovation Awards

The Lupus Research Alliance proudly announced today the 2020 Lupus Innovation Awards. The projects represent a wide breadth of scientific exploration in lupus, probing the development and progression of lupus while pointing to potential treatment approaches.

10 Nov 2020

Novel 3D-printed scaffold loaded with chemotherapy drug could reduce breast cancer recurrence

The recurrence of cancer after surgery is a major concern for patients. New findings from a QUT study have shown the potential for a novel 3D-printed porous scaffold which is loaded with a common chemotherapy drug that can reduce breast cancer recurrence in an experimental setting.

10 Nov 2020

PhoreMost and Oxford Biomedica collaborate to develop next-generation CAR-T cell therapies

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica plc, a leading gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies.

From PhoreMost 10 Nov 2020